News | November 06, 2024
Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Granules now has a total of 67 ANDA approvals from the USFDA
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
The recent inspection covered both cGMP and PAI processes
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Subscribe To Our Newsletter & Stay Updated
